LPAR1 and ovarian carcinoma: Another orally active LPA1 antagonist was reported with preclinical activity in pancreatic cancer (which have been shown to have higher levels of fibrosis), suggesting low levels of fibrosis in breast and ovarian cancers may be responsible herein [56].